News

01/30/2015

Congratulations to Dr. Saud A. Sadiq who has been recognized in Castle Connolly's "America's Top Doctors" 14th ed. and "Top Doctors: New York Metro Area" 18th ed.

The mission of Castle Connolly Medical Ltd. is to help consumers find the best healthcare. To this end, they publish a variety of books including the "Top Doctors" series, the most popular of which is America's Top Doctors®. The top doctors who are listed in their books and on their website's directory were nominated by... more

01/26/2015

Due to the impending storm and weather conditions, the IMSMP will be closed on Tuesday, January 27th. For any emergencies, a neurologist will be available by calling (212) 265-8070.

01/16/2015

1/16/15 - iConquerMS™ is a project associated with the Accelerated Cure Project. iConquerMS™ allows patients to independently enter their health data into a secure online database, where it will be analyzed in conjunction with that of thousands of others living with MS. In their words:

“iConquerMS™ is a novel way to fight multiple sclerosis, empowering people living with MS to securely contribute their health data and ideas to advance research. iConquerMS™ is part of a national... more

01/12/2015

by Dr. James W. Stark

1/12/15 - Biogen Idec has announced the interim results of their early phase trial with the medication, anti-Lingo-1, a drug that targets a protein involved in myelin regulation. The study is examining 32 patients with optic neuritis and is attempting to show actual repair of damaged nerve tissue with this treatment. The report states a 34% improvement in optic nerve processing time, but no change in nerve fiber layer thickness or visual acuity. However, the 34... more

01/08/2015

by Dr. James W. Stark

1/8/15 - The December 29th online issue of the journal, JAMA Neurology, published results on the safety and efficacy of a stem cell project currently funded by the National Institute of Health (NIH). This is valuable research in the field of Multiple Sclerosis, but is NOT the same as the phase I REPARATIVE stem cell trial currently underway at the IMSMP.

The NIH study examined 25 patients with early relapsing-remitting MS who had evidence of disease... more

12/19/2014

by Dr. James W. Stark

12/19/14 - If we have given or mailed you a prescription for bloodwork, please remember to have it done in a timely manner. Depending on your MS treatment, bloodwork may be very important for deciding how long to stay on a treatment or sometimes when to re-administer the treatment. Bloodwork is also very important for monitoring the safety of our immune-modifying drugs, especially with all of the new medications available today. In particular, the IMSMP... more

12/08/2014

12/8/14 - 'Tis the season for snow and less sunshine. Supplementing with vitamin D during these cold months becomes even more important. For the appropriate dose, check with your neurologist or IMSMP patients can schedule a consult with Dr. Bates, our naturopathic doctor.

11/25/2014

by Dr. James W. Stark

11/25/14 - Plegridy was recently approved by the FDA for the treatment of relapsing forms of MS and is now available for use. Plegridy is another interferon, specifically pegylated interferon B-1a. It is similar to other interferons currently available but is administered every two weeks by a subcutaneous injection. Side effects were similar to other interferons, however, because it is administered every two weeks, side effects were seen less frequently than... more

11/17/2014

11/17/14 - The FDA has approved Lemtrada (Alemtuzumab) for the treatment of RRMS. Lemtrada has been available to treat MS in Europe and Canada and has also been used in the United States to treat leukemia. Lemtrada will likely be reserved for patients with very aggressive forms of relapsing MS, as there are a number of safety considerations with this medication.

11/17/2014

11/17/14 - Dr. Armistead Williams has been named by New York Super Doctors® as one of the rising star doctors in New York for 2014. The number of doctors receiving this honor is limited to approximately five percent of the region’s active physicians.

 

Each year, Key Professional Media undertakes a rigorous multi-phase selection process that includes a survey of doctors, independent evaluation of candidates by the research staff, a peer review of candidates by practice area... more

Pages

IMSMP

Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.